Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31) 31
science & technology (29) 29
life sciences & biomedicine (26) 26
biological and medical sciences (21) 21
oncology (19) 19
male (15) 15
middle aged (15) 15
aged (14) 14
medical sciences (14) 14
adult (13) 13
female (13) 13
chemistry (8) 8
performing operations (8) 8
transporting (8) 8
animal and vegetable oils, fats, fatty substances and waxes (7) 7
animals (7) 7
candles (7) 7
chemical or physical processes, e.g. catalysis or colloidchemistry (7) 7
compounds thereof (7) 7
detergent compositions (7) 7
detergents (7) 7
fatty acids therefrom (7) 7
fundamental and applied biological sciences. psychology (7) 7
genetics & heredity (7) 7
inorganic chemistry (7) 7
metallurgy (7) 7
molecular sequence data (7) 7
non-metallic elements (7) 7
physical or chemical processes or apparatus in general (7) 7
recovery of glycerol (7) 7
resin soaps (7) 7
soap or soap-making (7) 7
their relevant apparatus (7) 7
tumors (7) 7
use of single substances as detergents (7) 7
base sequence (6) 6
benzamides (6) 6
imatinib mesylate (6) 6
mice (6) 6
survival analysis (6) 6
treatment outcome (6) 6
aged, 80 and over (5) 5
antineoplastic agents - therapeutic use (5) 5
chromosomes, human, pair 3 (5) 5
gastrointestinal stromal tumors - drug therapy (5) 5
hematology (5) 5
imatinib (5) 5
tumor cells, cultured (5) 5
carcinoma, renal cell - genetics (4) 4
chromosome mapping (4) 4
chromosomes, human, pair 3 - genetics (4) 4
clinical medicine (4) 4
clinical trials (4) 4
follow-up studies (4) 4
gastrointestinal neoplasms - drug therapy (4) 4
gastrointestinal stromal tumors - surgery (4) 4
gene expression (4) 4
genes, tumor suppressor (4) 4
kidney neoplasms - genetics (4) 4
klinisk medicin (4) 4
medical and health sciences (4) 4
medicin och hälsovetenskap (4) 4
mice, nude (4) 4
molecular and cellular biology (4) 4
neoplasm metastasis (4) 4
pharmacology. drug treatments (4) 4
polymerase chain reaction (4) 4
abridged index medicus (3) 3
analysis (3) 3
antineoplastic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
cancer (3) 3
cancer and oncology (3) 3
cancer och onkologi (3) 3
chemotherapy (3) 3
chemotherapy, adjuvant (3) 3
classical genetics, quantitative genetics, hybrids (3) 3
cloning, molecular (3) 3
cytidine deaminase (3) 3
cytosine arabinoside (3) 3
drug administration schedule (3) 3
drug resistance (3) 3
gastroenterology. liver. pancreas. abdomen (3) 3
gastrointestinal stromal tumors - pathology (3) 3
gene amplification (3) 3
gene transfer techniques (3) 3
genetics of eukaryotes. biological and molecular evolution (3) 3
gist (3) 3
human (3) 3
in situ hybridization, fluorescence (3) 3
kidneys (3) 3
methods of producing paper thereon (3) 3
paper-making (3) 3
paper-making machines (3) 3
piperazines - administration & dosage (3) 3
pneumology (3) 3
production of cellulose (3) 3
proteins - genetics (3) 3
proto-oncogenes (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
by Schuler, Martin and Awada, Ahmad and Harter, Philipp and Canon, Jean Luc and Possinger, Kurt and Schmidt, Marcus and De Grève, Jacques and Neven, Patrick and Dirix, Luc and Jonat, Walter and Beckmann, Matthias W and Schütte, Jochen and Fasching, Peter A and Gottschalk, Nina and Besse-Hammer, Tatiana and Fleischer, Frank and Wind, Sven and Uttenreuther-Fischer, Martina and Piccart, Martine and Harbeck, Nadia
Breast cancer research and treatment, ISSN 0167-6806, 8/2012, Volume 134, Issue 3, pp. 1149 - 1159
EGFR TKI | Medicine & Public Health | Afatinib | Oncology | Metastatic breast cancer | HER2-negative breast cancer | Triple-negative breast cancer | Life Sciences & Biomedicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - metabolism | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Treatment Outcome | Breast Neoplasms - drug therapy | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - deficiency | Cohort Studies | Medical research | Chemotherapy | Analysis | Estrogen | Clinical trials | Medicine, Experimental | Breast cancer | Metastasis | Cancer | Index Medicus | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial
by Joensuu, Heikki and Eriksson, Mikael and Hall, Kirsten Sundby and Hartmann, Jörg T and Pink, Daniel and Schütte, Jochen and Ramadori, Giuliano and Hohenberger, Peter and Duyster, Justus and Al-Batran, Salah-Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Sarlomo-Rikala, Maarit and Nilsson, Bengt and Sihto, Harri and Monge, Odd R and Bono, Petri and Kallio, Raija and Vehtari, Aki and Leinonen, Mika and Alvegar̊d, Thor and Reichardt, Peter
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Tumors | Pathology | tumors | Hospitals | Reviews | Safety engineering | survival | Mutation | intervention | surgery
Journal Article
Details down arrow
3. Full Text Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
by Joensuu, Heikki and Eriksson, Mikael and Hall, Kirsten Sundby and Hartmann, Jörg T and Pink, Daniel and Schütte, Jochen and Ramadori, Giuliano and Hohenberger, Peter and Duyster, Justus and Al‐Batran, Salah‐Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Sarlomo‐Rikala, Maarit and Nilsson, Bengt and Sihto, Harri and Ballman, Karla V and Leinonen, Mika and DeMatteo, Ronald P and Reichardt, Peter
Cancer, ISSN 0008-543X, 08/2014, Volume 120, Issue 15, pp. 2325 - 2333
imatinib | adjuvant therapy | predictive score | gastrointestinal stromal tumor | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Piperazines - administration & dosage | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Pyrimidines - administration & dosage | Humans | Middle Aged | Risk Factors | Male | Antineoplastic Agents - administration & dosage | Imatinib Mesylate | Neoplasm Recurrence, Local - pathology | Benzamides - administration & dosage | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - pathology | Female | Chemotherapy, Adjuvant | Research | Drug therapy | Gastrointestinal tumors | Patient outcomes | Risk factors | Index Medicus | Abridged Index Medicus | Original | score | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | predictive | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence?
by Eriksson, Mikael and Reichardt, Peter and Sundby Hall, Kirsten and Schütte, Jochen and Cameron, Silke and Hohenberger, Peter and Bauer, Sebastian and Leinonen, Mika and Reichardt, Annette and Rejmyr Davis, Maria and Alvegård, Thor and Joensuu, Heikki
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 59, pp. 128 - 133
Hematology, Oncology and Palliative Medicine | Risk of recurrence | GIST | Imatinib | Adjuvant | Gastrointestinal stromal tumour | Needle biopsy | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastrointestinal Neoplasms - prevention & control | Neoplasm Seeding | Gastrointestinal Neoplasms - mortality | Humans | Risk Factors | Kaplan-Meier Estimate | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Abdominal Wall | Neoplasm Recurrence, Local - mortality | Biopsy, Needle - methods | Neoplasm Recurrence, Local - etiology | Magnetic Resonance Imaging | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gastrointestinal Stromal Tumors - pathology | Biopsy, Needle - adverse effects | Female | Gastrointestinal Stromal Tumors - mortality | Tyrosine | Relapse | Sarcoma | Diagnosis | Epidemiology | Cancer | Diseases | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Surgery | Kirurgi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Radioembolization in Patients with Progressive Gastrointestinal Stromal Tumor Liver Metastases Undergoing Treatment with Tyrosine Kinase Inhibitors
by Rathmann, Nils, MD and Diehl, Steffen J., MD and Dinter, Dietmar, MD and Schütte, Jochen, MD and Pink, Daniel, MD and Schoenberg, Stefan O., MD and Hohenberger, Peter, MD
Journal of vascular and interventional radiology, ISSN 1051-0443, 2015, Volume 26, Issue 2, pp. 231 - 238
Radiology | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Chemoradiotherapy - methods | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Treatment Outcome | Liver Neoplasms - therapy | Gastrointestinal Neoplasms - therapy | Chemoembolization, Therapeutic - methods | Angiogenesis Inhibitors - administration & dosage | Gastrointestinal Stromal Tumors - therapy | Liver Neoplasms - diagnosis | Gastrointestinal Stromal Tumors - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Aged | Liver Neoplasms - secondary | Yttrium Radioisotopes - therapeutic use | Radiopharmaceuticals - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
by Bauer, Sebastian and Hartmann, Jörg Thomas and de Wit, Maike and Lang, Hauke and Grabellus, Florian and Antoch, Gerald and Niebel, Wolfgang and Erhard, Jochen and Ebeling, Peter and Zeth, Matthias and Taeger, Georg and Seeber, Siegfried and Flasshove, Michael and Schütte, Jochen
International journal of cancer, ISSN 0020-7136, 11/2005, Volume 117, Issue 2, pp. 316 - 325
imatinib | resection | GIST | Imatinib | Resection | Biological and medical sciences | Medical sciences | Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases | Surgery of the digestive system | Stomach, duodenum, intestine, rectum, anus | Tumors | Gastrointestinal Stromal Tumors - surgery | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Neoplasm Metastasis | Time Factors | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Gastrointestinal Stromal Tumors - pathology | Neoplasm, Residual - drug therapy | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Benzamides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)
by Schmitt, Thomas and Mayer-Steinacker, Regine and Mayer, Frank and Grünwald, Viktor and Schütte, Jochen and Hartmann, Jörg T and Kasper, Bernd and Hüsing, Johannes and Hajda, Jacek and Ottawa, Gregor and Mechtersheimer, Gunhild and Mikus, Gerd and Burhenne, Jürgen and Lehmann, Lorenz and Heilig, Christoph E and Ho, Anthony D and Egerer, Gerlinde
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 64, pp. 74 - 82
Hematology, Oncology and Palliative Medicine | Soft Tissue Sarcoma | Metastatic | Histone deacetylase-inhibition | Vorinostat | Locally advanced | Life Sciences & Biomedicine | Oncology | Science & Technology | Sarcoma - secondary | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Soft Tissue Neoplasms - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Sarcoma - drug therapy | Sarcoma - pathology | Young Adult | Antineoplastic Agents - adverse effects | Soft Tissue Neoplasms - pathology | Survival Analysis | Aged, 80 and over | Adult | Female | Hydroxamic Acids - therapeutic use | Aged | Germany | Clinical trials | Metastasis | Sarcoma | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial
by Hüttmann, Andreas and Rekowski, Jan and Müller, Stefan P and Hertenstein, Bernd and Franzius, Christiane and Mesters, Rolf and Weckesser, Matthias and Kroschinsky, Frank and Kotzerke, Jörg and Ganser, Arnold and Bengel, Frank M and La Rosée, Paul and Freesmeyer, Martin and Höffkes, Heinz-Gert and Hertel, Andreas and Behringer, Dirk and Prange-Krex, Gabriele and Griesshammer, Martin and Holzinger, Jens and Wilop, Stefan and Krohn, Thomas and Raghavachar, Aruna and Maschmeyer, Georg and Brink, Ingo and Schroers, Roland and Gaska, Tobias and Bernhard, Helga and Giagounidis, Aristoteles and Schütte, Jochen and Dienst, Ariane and Hautzel, Hubertus and Naumann, Ralph and Klein, Alfred and Hahn, Dennis and Pöpperl, Gabriele and Grube, Matthias and Marienhagen, Jörg and Schwarzer, Andreas and Kurch, Lars and Höhler, Thomas and Steiniger, Heike and Nückel, Holger and Südhoff, Thomas and Römer, Wolfgang and Brinkmann, Marcus and Ose, Claudia and Alashkar, Ferras and Schmitz, Christine and Dürig, Jan and Hoelzer, Dieter and Jöckel, Karl-Heinz and Klapper, Wolfram and Dührsen, Ulrich
Annals of hematology, ISSN 0939-5555, 4/2019, Volume 98, Issue 4, pp. 897 - 907
Medicine & Public Health | Hematology | Primary mediastinal B cell lymphoma | R-CHOP | Follicular lymphoma | Rituximab | Oncology | Diffuse large B cell lymphoma | Survival | Life Sciences & Biomedicine | Science & Technology | Fluorodeoxyglucose F18 - administration & dosage | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, B-Cell - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Survival Rate | Positron-Emission Tomography | Rituximab - administration & dosage | Disease-Free Survival | Adolescent | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Aged | Lymphoma, B-Cell - diagnostic imaging | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Clinical trials | Tomography | Analysis | Lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia
by Schroder, Jan K and Kirch, Christoph and Seeber, Siegfried and Schutte, Jochen
British journal of haematology, ISSN 0007-1048, 12/1998, Volume 103, Issue 4, pp. 1096 - 1103
cytidine deaminase | drug resistance | acute myeloid leukaemia | cytosine arabinoside | Acute myeloid leukaemia | Cytosine arabinoside | Drug resistance | Cytidine deaminase | Life Sciences & Biomedicine | Hematology | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Blotting, Southern | Acute Disease | Cytarabine - therapeutic use | Leukemia, Myeloid - enzymology | Cytidine Deaminase - genetics | Humans | Leukemia, Myeloid - genetics | Middle Aged | Drug Resistance, Neoplasm | Mutation - genetics | Polymorphism, Genetic | Antimetabolites, Antineoplastic - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Reverse Transcriptase Polymerase Chain Reaction - methods | Adult | Aged | Idarubicin - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
by Joensuu, Heikki and Eriksson, Mikael and Sundby Hall, Kirsten and Reichardt, Annette and Hermes, Barbara and Schütte, Jochen and Cameron, Silke and Hohenberger, Peter and Jost, Philipp J and Al-Batran, Salah-Eddin and Lindner, Lars H and Bauer, Sebastian and Wardelmann, Eva and Nilsson, Bengt and Kallio, Raija and Jaakkola, Panu and Junnila, Jouni and Alvegård, Thor and Reichardt, Peter
JAMA oncology, 08/2020, Volume 6, Issue 8, p. 1241
Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Middle Aged | Gastrointestinal Neoplasms - surgery | Male | Risk | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Gastrointestinal Stromal Tumors - drug therapy | Fusion Proteins, bcr-abl - antagonists & inhibitors | Imatinib Mesylate - administration & dosage | Survival Analysis | Female | Aged | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - mortality
Journal Article
Details down arrow
11. Full Text Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
by Bauer, Sebastian and Corless, Christopher L and Heinrich, Michael C and Dirsch, Olaf and Antoch, Gerald and Kanja, Jörg and Seeber, Siegfried and Schütte, Jochen
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 3/2003, Volume 51, Issue 3, pp. 261 - 265
Gastrointestinal stromal tumor GIST Imatinib KIT immunonegativity | GIST | Imatinib | KIT immunonegativity | Gastrointestinal stromal tumor | Pharmacology & Pharmacy | Oncology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Chemotherapy | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Immunohistochemistry | Frameshift Mutation | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Gene Expression Regulation | Male | Pyrimidines - pharmacology | Proto-Oncogene Proteins c-kit - biosynthesis | Imatinib Mesylate | Piperazines - pharmacology | Stromal Cells | DNA Mutational Analysis | Adult | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Benzamides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Design studies and multi-disciplinary assessment of agile and highly swept flying wing configurations
by Liersch, Carsten M and Schütte, Andreas and Siggel, Martin and Dornwald, Jochen
CEAS aeronautical journal, ISSN 1869-5582, 09/2020, Volume 11, Issue 3, pp. 781 - 802
Combat aircraft | Research projects | Aerodynamics | Unmanned aerial vehicles | Aircraft design | Topology | Design analysis | Configurations | Aircraft
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights